| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1017784622 |
| P356 | DOI | 10.1186/ALZRT214 |
| P932 | PMC publication ID | 3978816 |
| P698 | PubMed publication ID | 24152385 |
| P5875 | ResearchGate publication ID | 258038237 |
| P50 | author | Bradley Hyman | Q23303113 |
| Tara L Spires-Jones | Q42586954 | ||
| Amy M Pooler | Q74787777 | ||
| Susanne Wegmann | Q87854356 | ||
| Manuela Polydoro | Q117206235 | ||
| Samantha B Nicholls | Q117206242 | ||
| P2860 | cites work | Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain | Q24310491 |
| Proteomic analysis of exosomes from human neural stem cells by flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry | Q24324058 | ||
| Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes | Q24608787 | ||
| Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells | Q24610255 | ||
| Transmission and spreading of tauopathy in transgenic mouse brain | Q24651334 | ||
| Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein | Q24655848 | ||
| Mechanisms of protein seeding in neurodegenerative diseases | Q26994962 | ||
| Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers | Q27008249 | ||
| Tau and tauopathies | Q27027415 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells | Q28118982 | ||
| Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 | ||
| Trans-synaptic spread of tau pathology in vivo | Q28732288 | ||
| Tau suppression in a neurodegenerative mouse model improves memory function | Q29615831 | ||
| Propagation of tau pathology in a model of early Alzheimer's disease | Q29620203 | ||
| Dynamic association of tau with neuronal membranes is regulated by phosphorylation | Q30155626 | ||
| Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice | Q34102829 | ||
| Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau | Q34186650 | ||
| Alzheimer's disease: cell-specific pathology isolates the hippocampal formation | Q34261572 | ||
| Hyperphosphorylation and cleavage at D421 enhance tau secretion | Q34277477 | ||
| Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits | Q34430288 | ||
| Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles | Q34869120 | ||
| Caspase activation precedes and leads to tangles | Q34965124 | ||
| In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice | Q34985153 | ||
| Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease | Q35763138 | ||
| Trans-cellular propagation of Tau aggregation by fibrillar species | Q36003836 | ||
| Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain | Q36005623 | ||
| The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system | Q36295481 | ||
| Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies | Q36466732 | ||
| Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons | Q36543778 | ||
| Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature | Q36575903 | ||
| Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy | Q36617500 | ||
| Cell-to-cell propagation of infectious cytosolic protein aggregates | Q36762492 | ||
| Brain homogenates from human tauopathies induce tau inclusions in mouse brain | Q36915421 | ||
| Prion-like propagation of protein aggregation and related therapeutic strategies | Q36983208 | ||
| Synaptic alterations in the rTg4510 mouse model of tauopathy | Q37051901 | ||
| Calcium phosphatase calcineurin influences tau metabolism | Q37427768 | ||
| Classification and basic pathology of Alzheimer disease | Q37453000 | ||
| Prion-like mechanisms in neurodegenerative diseases | Q37661351 | ||
| Functional implications of the association of tau with the plasma membrane. | Q37775663 | ||
| Cellular mechanisms of protein aggregate propagation | Q38056356 | ||
| Progress and developments in tau aggregation inhibitors for Alzheimer disease | Q38088711 | ||
| The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. | Q38092945 | ||
| Developing therapeutic antibodies for neurodegenerative disease | Q38095360 | ||
| Exosomes: mediators of communication in eukaryotes | Q38113951 | ||
| The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein | Q38424405 | ||
| Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. | Q38674158 | ||
| Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. | Q39433741 | ||
| Physiological release of endogenous tau is stimulated by neuronal activity. | Q39560268 | ||
| Interneuronal transfer of human tau between Lamprey central neurons in situ | Q39746642 | ||
| Propagation of tau misfolding from the outside to the inside of a cell. | Q39873721 | ||
| Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules | Q40665458 | ||
| Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model | Q40796484 | ||
| Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau | Q41979763 | ||
| Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation | Q42130064 | ||
| The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease | Q42470207 | ||
| Multiple mechanisms of extracellular tau spreading in a non-transgenic tauopathy model. | Q43103264 | ||
| Characteristics and consequences of muscarinic receptor activation by tau protein. | Q46021391 | ||
| Exosomes are released by cultured cortical neurones. | Q46918951 | ||
| CaMKII activation in the entorhinal cortex disrupts previously encoded spatial memory | Q48573231 | ||
| Memory-related neural systems in Alzheimer's disease: an anatomic study | Q48866916 | ||
| Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization | Q49169032 | ||
| Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. | Q53200382 | ||
| Constitutive secretion of tau protein by an unconventional mechanism. | Q54306723 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathology | Q7208 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 49 | |
| P577 | publication date | 2013-10-23 | |
| P1433 | published in | Alzheimers Research & Therapy | Q15716761 |
| P1476 | title | Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets | |
| P478 | volume | 5 |
| Q41599510 | Cypermethrin Stimulates GSK3β-Dependent Aβ and p-tau Proteins and Cognitive Loss in Young Rats: Reduced HB-EGF Signaling and Downstream Neuroinflammation as Critical Regulators |
| Q90591149 | Development of disease-modifying drugs for frontotemporal dementia spectrum disorders |
| Q55333133 | Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies. |
| Q36970998 | High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease |
| Q33640390 | Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency |
| Q36164278 | Identification of disulfide cross-linked tau dimer responsible for tau propagation |
| Q38263698 | Invited review: Drug development for tauopathies |
| Q57560752 | Mapping interactions with the chaperone network reveals factors that protect against tau aggregation |
| Q98280964 | Multiscale causal networks identify VGF as a key regulator of Alzheimer's disease |
| Q53384509 | Neurodegenerative disorders: Neural synchronization in Alzheimer's disease. |
| Q92191065 | Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments |
| Q36169754 | Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain |
| Q52613291 | Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. |
| Q91612343 | Organotypic brain slice cultures to model neurodegenerative proteinopathies |
| Q99585475 | Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer's disease models |
| Q92239941 | Pathogenic Tau Protein Species: Promising Therapeutic Targets for Ocular Neurodegenerative Diseases |
| Q38942540 | Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases |
| Q38922025 | Prion-like propagation as a pathogenic principle in frontotemporal dementia. |
| Q47926474 | Small-molecule PET Tracers for Imaging Proteinopathies |
| Q39379363 | Spreading of Pathology in Alzheimer's Disease |
| Q37736091 | Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. |
| Q48214662 | Tau peptides and tau mutant protein aggregation inhibition by cationic polyethyleneimine and polyarginine. |
| Q40278614 | Tau protein as a target for Alzheimer's disease management |
| Q54977832 | The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. |
| Q35662607 | The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. |
| Q26796582 | The genetic landscape of Alzheimer disease: clinical implications and perspectives |
| Q34054680 | The intersection of amyloid beta and tau at synapses in Alzheimer's disease |
| Q28083428 | The preclinical phase of the pathological process underlying sporadic Alzheimer's disease |
| Q64102453 | Toward a Glutamate Hypothesis of Frontotemporal Dementia |
| Q59356932 | Viral Hypothesis and Antiviral Treatment in Alzheimer's Disease |
Search more.